
| UNAIDS-Sponsored Regional Workshops to Discuss Ethical Issues in Preventive HIV Vaccine Trials (UNAIDS, 2000, 52 p.) |
| (introduction...) |
| INTRODUCTION |
![]() | Purpose of the Workshops |
![]() | Participants |
![]() | Workshop Methodology |
![]() | Reading this Report |
| SUMMARY |
| WORKSHOP REPORTS |
![]() | OURO PRETO, BRAZIL, 1-3 APRIL, 1998 |
![]() | 1. Vulnerability to Harm or Exploitation |
![]() | 2. Collaboration in Phase I/II (Safety and Immunogenicity) Trials |
![]() | 3. Phase III (efficacy) Trials |
![]() | 4. Review of Vaccine Trials |
![]() | 5. Candidate Vaccine Choice |
![]() | 6. Community |
![]() | 7. Intellectual Property |
![]() | 8. Control Arm in Trials |
![]() | 9. Informed Consent |
![]() | 10. Gender, Pregnancy and Breast-Feeding |
![]() | 11. Counselling, Treatment and Care |
![]() | 12. Access and Availability of Vaccine |
![]() | 13. Items Not Discussed |
![]() | BANGKOK, THAILAND, 20-22 APRIL, 1998 |
![]() | 1. Collaboration in Phase I, II and III Trials |
![]() | 2. Community |
![]() | 3. Ethical and Scientific Review |
![]() | 4. Intellectual Property |
![]() | 5. Control Arm in Trials |
![]() | 6. Informed Consent |
![]() | 7. Gender, Pregnancy and Breast-Feeding |
![]() | 8. Children |
![]() | 9. Protection from Discrimination |
![]() | 10. Vaccine-Induced HIV-Seropositivity |
![]() | 11. Counselling |
![]() | 12. Post-Exposure Prophylaxis (PEP) |
![]() | 13. Treatment and Care |
![]() | 14. Compensation |
![]() | 15. Availability of Vaccine |
![]() | ENTEBBE, UGANDA, 27-29 APRIL, 1998 |
![]() | 1. Phase I/II (Safety and Immunogenicity) Trials |
![]() | 2. Phase III Trials |
![]() | 3. Vulnerability to Harm and Exploitation |
![]() | 4. Community |
![]() | 5. Ethical Review |
![]() | 6. Intellectual Property |
![]() | 7. Control Arm in Trials |
![]() | 8. Informed Consent |
![]() | 9. Counselling |
![]() | 10. Gender, Pregnancy and Breast-Feeding |
![]() | 11. Children |
![]() | 12. Discrimination |
![]() | 13. Treatment and Care |
![]() | 14. Endpoints in Vaccine Trials |
![]() | 15. Compensation for Injury or Harm |
![]() | 16. Access and Availability of Vaccine |
| ANNEX 1: CASE SCENARIO AND DISCUSSION QUESTIONS |
![]() | Case Scenario |
![]() | Discussion Questions |
| ANNEX 2: WORKSHOP EVALUATIONS |
![]() | Workshop Evaluation, Brazil |
![]() | Workshop Evaluation, Thailand |
![]() | Workshop Evaluation, Uganda |
| ANNEX 3: LIST OF PARTICIPANTS |
![]() | List of Participants, Brazil |
![]() | List of Participants, Thailand |
![]() | List of Participants, Uganda |
Consensus:
The circumstances under which compensation will be provided, and the type and level of compensation, must be described in the study protocol and in the information for consent.
Discussion:
Discussion centred primarily on harm of a social nature. Socially adverse events will generally result from discrimination based on perceived or actual HIV status. There needs to be adequate individual counselling and sensitization of the community to issues that may arise through involvement in HIV vaccine trials.
Where social harm results from apparent breach of confidentiality, it would be important to determine whether there was negligence on the part of the research team. Although this may be very difficult to accomplish, attempts should be made to do so, and compensation should be provided for cases where negligence was involved.
It was suggested that a Data and Safety Monitoring Board might take the responsibility of determining whether negligence was involved in a specific case or not, though it was acknowledged that this would be a new practice for such a body.
It was suggested that there needs to be a mechanism to ensure exclusion of those individuals who do not have an adequate understanding of the potential risks of participation in the trial.